Titre:
  • Subgroup analyses from a phase 3, open-label, randomized study of eribulin mesylate versus capecitabine in pretreated patients with advanced or metastatic breast cancer
Auteur:Twelves, Chris; Awada, Ahmad; Cortes, Javier; Yelle, Louise; Velikova, Galina; Olivo, Martin M.S.; Song, James; Dutcus, Corina C.E.; Kaufman, Peter P.A.
Informations sur la publication:Breast Cancer, 10, page (77-84)
Statut de publication:Publié, 2016-06
Sujet CREF:Cancérologie
Mots-clés:Advanced/metastatic breast cancer
Capecitabine
Eribulin
Human epidermal growth factor receptor 2
Subgroup analyses
Survival
Note générale:SCOPUS: ar.j
Langue:Anglais
Identificateurs:urn:issn:1178-2234
info:doi/10.4137/BCBCR.S39615
info:scp/84992088913